Effect of Maqliasa capsule on ulcerative colitis

Effect of Maqliasa - a traditional Persian medicine formulation on ulcerative colitis: A pilot clinical study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017042719489N2

Enrollment

Registered

2017-07-09

Start date

2017-06-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis

Interventions

Herbal product capsules called "Maqliasa" -2 capsules three times daily orally for intervention group -There is no control group -Duration of intervention: 28 days -Manufacturer: Barij Essence Pharma

Treatment - Drugs

Herbal product capsules called "Maqliasa" -2 capsules three times daily orally for intervention group -There is no control group -Duration of intervention: 28 days -Manufacturer: Barij Essence Ph

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- The study is accomplished in patients suffer from ulcerative colitis confirmed by colonoscopy 2- Age limit between 18 to 70 y/o 3- No pregnancy 4- No breastfeeding 5- No history of peptic ulcer 6- No history of toxic megacolon 7- No history of colon cancer Exclusion criteria: 1- Appearance of peptic ulcer manifestations 2- Emergence of severe drug complications

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Diarrhea (Number of daily stools). Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Nocturnal diarrhea. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Fecal incontinence. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Abdominal pain or cramping. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;General well-being. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Abdominal tenderness. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Physical exam.;Need for anti-diarrhea drugs. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.	—

Measure

Time frame

Diarrhea (Number of daily stools). Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Nocturnal diarrhea. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Fecal incontinence. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Abdominal pain or cramping. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;General well-being. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.;Abdominal tenderness. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Physical exam.;Need for anti-diarrhea drugs. Timepoint: Onset of intervention, 14 and 28 days later. Method of measurement: Patient statements.

—

Secondary

Measure	Time frame
Adverse drug reactions. Timepoint: Days 14th and 28th. Method of measurement: Patient statements.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammadmahdi Ahmadian-Attari

Alborz university of medical sciences

ahmadian-attari@gmail.com+98 21 4427 1724

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026